MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2022
Mind Cure Health Inc. (CSE: MCUR, OTCQX: MCURF) reported its financial results for the three and nine months ending February 28, 2022. Key highlights include ongoing development in the psychedelics industry and work on synthesizing ibogaine, which aims to address mental health treatments. The company acknowledges potential risks, including COVID-19's impact and regulatory changes that could affect operations. Forward-looking statements caution against over-reliance on anticipated outcomes, emphasizing uncertainty in achieving projected timelines and market demand.
- Ongoing development of iSTRYM targeting psychedelics market.
- Focus on synthesizing ibogaine for mental health solutions.
- COVID-19 pandemic impact on business operations remains uncertain.
- Dependence on future market demand for products.
VANCOUVER, BC, April 26, 2022 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and nine months ended February 28, 2022. All amounts are stated in Canadian dollars unless otherwise indicated.
A copy of the Company's financial statements for the three and nine months ended February 28, 2022 and the related management's discussion and analysis are available under the Company's profile on SEDAR at www.sedar.com.
On Behalf of the Board of Directors
Philip Tapley, Interim CEO
Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the time frame contemplated.
Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindcure-announces-financial-results-for-the-third-quarter-of-fiscal-2022-301533775.html
SOURCE Mind Cure Health Inc.
FAQ
What are the financial results of Mind Cure Health for the third quarter of 2022?
What challenges does Mind Cure Health face according to the recent press release?
What is the future outlook for Mind Cure Health's product development?
